Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.
Identifieur interne : 000067 ( Main/Exploration ); précédent : 000066; suivant : 000068Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.
Auteurs : Joshua F. Craft [États-Unis] ; Mark A. Travassos [États-Unis] ; Carlo Foppiano Palacios [États-Unis] ; John J. Openshaw [États-Unis]Source :
- The American journal of tropical medicine and hygiene [ 1476-1645 ] ; 2021.
Descripteurs français
- KwdFr :
- Afro-Américains (MeSH), Disparités d'accès aux soins (MeSH), Essais cliniques comme sujet (normes), Essais cliniques comme sujet (organisation et administration), Ethnies (statistiques et données numériques), Hispano-américain (MeSH), Humains (MeSH), Minorités (MeSH), Plan de recherche (MeSH), États-Unis (épidémiologie).
- MESH :
- normes : Essais cliniques comme sujet.
- organisation et administration : Essais cliniques comme sujet.
- statistiques et données numériques : Ethnies.
- épidémiologie : États-Unis.
- Afro-Américains, Disparités d'accès aux soins, Hispano-américain, Humains, Minorités, Plan de recherche.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- African Americans (MeSH), American Natives (MeSH), COVID-19 (epidemiology), COVID-19 (prevention & control), COVID-19 Vaccines (immunology), Clinical Trials as Topic (organization & administration), Clinical Trials as Topic (standards), Ethnic Groups (statistics & numerical data), Healthcare Disparities (MeSH), Hispanic Americans (MeSH), Humans (MeSH), Minority Groups (MeSH), Research Design (MeSH), SARS-CoV-2 (immunology), United States (epidemiology).
- MESH :
- chemical , immunology : COVID-19 Vaccines.
- geographic , epidemiology : United States.
- epidemiology : COVID-19.
- immunology : SARS-CoV-2.
- organization & administration : Clinical Trials as Topic.
- prevention & control : COVID-19.
- standards : Clinical Trials as Topic.
- statistics & numerical data : Ethnic Groups.
- African Americans, American Natives, Healthcare Disparities, Hispanic Americans, Humans, Minority Groups, Research Design.
Abstract
Minority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasize the need for inclusion of minority groups in these trials, but none of the publicly available SARS-CoV-2 vaccine trial protocols requires representative sampling of minorities. This piece emphasizes the importance of adequate inclusion of minority communities in SARS-CoV-2 vaccine trials, and the implications of this inclusion for SARS-CoV-2 vaccine distribution.
DOI: 10.4269/ajtmh.20-1294
PubMed: 33200726
PubMed Central: PMC7790086
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.</title><author><name sortKey="Craft, Joshua F" sort="Craft, Joshua F" uniqKey="Craft J" first="Joshua F" last="Craft">Joshua F. Craft</name><affiliation wicri:level="2"><nlm:affiliation>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Travassos, Mark A" sort="Travassos, Mark A" uniqKey="Travassos M" first="Mark A" last="Travassos">Mark A. Travassos</name><affiliation wicri:level="2"><nlm:affiliation>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Foppiano Palacios, Carlo" sort="Foppiano Palacios, Carlo" uniqKey="Foppiano Palacios C" first="Carlo" last="Foppiano Palacios">Carlo Foppiano Palacios</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Infectious Diseases Section, Yale School of Medicine, New Haven, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Internal Medicine, Infectious Diseases Section, Yale School of Medicine, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Openshaw, John J" sort="Openshaw, John J" uniqKey="Openshaw J" first="John J" last="Openshaw">John J. Openshaw</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33200726</idno><idno type="pmid">33200726</idno><idno type="doi">10.4269/ajtmh.20-1294</idno><idno type="pmc">PMC7790086</idno><idno type="wicri:Area/Main/Corpus">000161</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000161</idno><idno type="wicri:Area/Main/Curation">000161</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000161</idno><idno type="wicri:Area/Main/Exploration">000161</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.</title><author><name sortKey="Craft, Joshua F" sort="Craft, Joshua F" uniqKey="Craft J" first="Joshua F" last="Craft">Joshua F. Craft</name><affiliation wicri:level="2"><nlm:affiliation>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Travassos, Mark A" sort="Travassos, Mark A" uniqKey="Travassos M" first="Mark A" last="Travassos">Mark A. Travassos</name><affiliation wicri:level="2"><nlm:affiliation>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Foppiano Palacios, Carlo" sort="Foppiano Palacios, Carlo" uniqKey="Foppiano Palacios C" first="Carlo" last="Foppiano Palacios">Carlo Foppiano Palacios</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Infectious Diseases Section, Yale School of Medicine, New Haven, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Internal Medicine, Infectious Diseases Section, Yale School of Medicine, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Openshaw, John J" sort="Openshaw, John J" uniqKey="Openshaw J" first="John J" last="Openshaw">John J. Openshaw</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford</wicri:cityArea></affiliation></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="eISSN">1476-1645</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African Americans (MeSH)</term><term>American Natives (MeSH)</term><term>COVID-19 (epidemiology)</term><term>COVID-19 (prevention & control)</term><term>COVID-19 Vaccines (immunology)</term><term>Clinical Trials as Topic (organization & administration)</term><term>Clinical Trials as Topic (standards)</term><term>Ethnic Groups (statistics & numerical data)</term><term>Healthcare Disparities (MeSH)</term><term>Hispanic Americans (MeSH)</term><term>Humans (MeSH)</term><term>Minority Groups (MeSH)</term><term>Research Design (MeSH)</term><term>SARS-CoV-2 (immunology)</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afro-Américains (MeSH)</term><term>Disparités d'accès aux soins (MeSH)</term><term>Essais cliniques comme sujet (normes)</term><term>Essais cliniques comme sujet (organisation et administration)</term><term>Ethnies (statistiques et données numériques)</term><term>Hispano-américain (MeSH)</term><term>Humains (MeSH)</term><term>Minorités (MeSH)</term><term>Plan de recherche (MeSH)</term><term>États-Unis (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>COVID-19 Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Essais cliniques comme sujet</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Essais cliniques comme sujet</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Ethnic Groups</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Ethnies</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>États-Unis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>African Americans</term><term>American Natives</term><term>Healthcare Disparities</term><term>Hispanic Americans</term><term>Humans</term><term>Minority Groups</term><term>Research Design</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Afro-Américains</term><term>Disparités d'accès aux soins</term><term>Hispano-américain</term><term>Humains</term><term>Minorités</term><term>Plan de recherche</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Minority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasize the need for inclusion of minority groups in these trials, but none of the publicly available SARS-CoV-2 vaccine trial protocols requires representative sampling of minorities. This piece emphasizes the importance of adequate inclusion of minority communities in SARS-CoV-2 vaccine trials, and the implications of this inclusion for SARS-CoV-2 vaccine distribution.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33200726</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of tropical medicine and hygiene</Title><ISOAbbreviation>Am J Trop Med Hyg</ISOAbbreviation></Journal><ArticleTitle>Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.</ArticleTitle><Pagination><MedlinePgn>32-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.20-1294</ELocationID><Abstract><AbstractText>Minority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasize the need for inclusion of minority groups in these trials, but none of the publicly available SARS-CoV-2 vaccine trial protocols requires representative sampling of minorities. This piece emphasizes the importance of adequate inclusion of minority communities in SARS-CoV-2 vaccine trials, and the implications of this inclusion for SARS-CoV-2 vaccine distribution.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Joshua F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Travassos</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foppiano Palacios</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Infectious Diseases Section, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Openshaw</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Trop Med Hyg</MedlineTA><NlmUniqueID>0370507</NlmUniqueID><ISSNLinking>0002-9637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086562" MajorTopicYN="N">American Natives</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnic Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054625" MajorTopicYN="N">Healthcare Disparities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic Americans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008913" MajorTopicYN="Y">Minority Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>17</Day><Hour>8</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33200726</ArticleId><ArticleId IdType="doi">10.4269/ajtmh.20-1294</ArticleId><ArticleId IdType="pmc">PMC7790086</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Connecticut</li><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Craft, Joshua F" sort="Craft, Joshua F" uniqKey="Craft J" first="Joshua F" last="Craft">Joshua F. Craft</name></region><name sortKey="Foppiano Palacios, Carlo" sort="Foppiano Palacios, Carlo" uniqKey="Foppiano Palacios C" first="Carlo" last="Foppiano Palacios">Carlo Foppiano Palacios</name><name sortKey="Openshaw, John J" sort="Openshaw, John J" uniqKey="Openshaw J" first="John J" last="Openshaw">John J. Openshaw</name><name sortKey="Travassos, Mark A" sort="Travassos, Mark A" uniqKey="Travassos M" first="Mark A" last="Travassos">Mark A. Travassos</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000067 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000067 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33200726
|texte= Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33200726" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |